Stephen Doberstein, Ph.D.
Stephen Doberstein, Ph.D., joined the Dicerna board of directors in February 2020. Dr. Doberstein currently serves as the Chief Scientific Fellow at Nektar Therapeutics, Inc. Prior to this, Dr. Doberstein was Nektar’s Senior Vice President of R&D and Chief Research and Development Officer, and he served for nearly eight years as Nektar’s Senior Vice President of Research and Chief Scientific Officer. During his tenure with the company, Dr. Doberstein has been responsible for all R&D efforts, supervising more than 300 scientists, physicians and support personnel.
Before joining Nektar, Dr. Doberstein was Vice President of Research at XOMA (US), LLC, Five Prime Therapeutics, Inc. and Xencor, Inc. He began his career in the pharmaceutical industry at Exelixis, Inc. as a Program Leader, rapidly advancing to roles of increasing responsibility in target research and discovery. Early in his career, Dr. Doberstein served as a Senior Engineer at E.I. duPont de Nemours & Co., Inc.
Dr. Doberstein received his bachelor’s degree in chemical engineering from the University of Delaware and his doctorate in biochemistry, cell and molecular biology from Johns Hopkins University School of Medicine. Dr. Doberstein was awarded the Howard Hughes Medical Institute Doctoral Fellowship and the Muscular Dystrophy Association Postdoctoral and Senior Postdoctoral Fellowships, and he has co-authored 30 research publications and review articles.